CIA
ACAD icon

Capital Impact Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Capital Impact Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,540
Closed -$399K – 2
2024
Q2 		$399K Buy
24,540
+14,854
+153% +$240K 1.12% 48
2024
Q1 		$179K Hold
9,686
– – 0.23% 87
2023
Q4 		$303K Hold
9,686
– – 0.4% 86
2023
Q3 		$202K Sell
9,686
-9,686
-50% -$263K 0.34% 98
2023
Q2 		$464K Hold
19,372
– – 0.51% 98
2023
Q1 		$365K Buy
19,372
+1,160
+6% +$22.1K 0.45% 107
2022
Q4 		$290K Sell
18,212
-2,842
-13% -$44.4K 0.28% 152
2022
Q3 		$315K Sell
21,054
-11,543
-35% -$187K 0.31% 134
2022
Q2 		$459K Buy
32,597
+3,643
+13% +$68K 0.42% 108
2022
Q1 		$701K Buy
28,954
+6,879
+31% +$166K 0.51% 92
2021
Q4 		$515K Buy
+22,075
New +$444K 0.36% 83

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Capital Impact Advisors's ACAD Position: Q3 2024 in Review

Capital Impact Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 24,540 shares — an estimated $399K sold.

Capital Impact Advisors first reported a position in ACAD in Q4 2021 and held it in 11 quarters. The position peaked at $701K in Q1 2022. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

  • Capital Impact Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Capital Impact Advisors sold 24,540 Acadia Pharmaceuticals shares in Q3 2024, an estimated $399K.
  • Capital Impact Advisors first reported a position in Acadia Pharmaceuticals in Q4 2021 and held it in 11 quarters.
  • Capital Impact Advisors's Acadia Pharmaceuticals position peaked at $701K in Q1 2022.
  • 256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on Capital Impact Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.